REFERENCES
1. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet . 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
2. Vera AM, Pardo C, Duarte MC, Suárez A. Análisis de la mortalidad por leucemia aguda pediátrica en el instituto nacional de cancerología.Biomedica . 2012;32(3):355-364. doi:10.7705/biomedica.v32i3.691
3. Sankaran H, Sengupta S, Purohit V, et al. A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia. Br J Clin Pharmacol . 2020;86(6):1081-1088. doi:10.1111/bcp.14216
4. Cecconello DK, Werlang ICR, Alegretti AP, et al. Monitoring asparaginase activity in middle-income countries. Lancet Oncol . 2018;19(9):1149-1150. doi:10.1016/S1470-2045(18)30584-9
5. Sidhu J, Gogoi MP, Agarwal P, et al. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer . 2021;68(11):1-9. doi:10.1002/pbc.29046
6. Michalowski MB, Cecconello DK, Lins MM, et al. Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study. Br J Haematol . 2021;194(1):168-173. doi:10.1111/bjh.17494
7. Lanvers-Kaminsky C, Rüffer A, Würthwein G, et al. Therapeutic Drug Monitoring of Asparaginase Activity - Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial . Vol 40.; 2018. doi:10.1097/FTD.0000000000000472
8. Chien WW, Le Beux C, Rachinel N, et al. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci Rep . 2015;5:19-21. doi:10.1038/srep08068
9. Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma . 2015;56(8):2273-2280. doi:10.3109/10428194.2014.1003056
10. Jiang J, Batra S, Zhang J. Asparagine: A metabolite to be targeted in cancers. Metabolites . 2021;11(6). doi:10.3390/metabo11060402
11. Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma, Myeloma Leuk . 2021;21(11):725-733. doi:10.1016/j.clml.2021.07.009
12. Muneer F, Siddique MH, Azeem F, et al. Microbial l-asparaginase: purification, characterization and applications. Arch Microbiol . 2020;202(5):967-981. doi:10.1007/s00203-020-01814-1
13. Tabe Y, Lorenzi PL, Konopleva M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood . 2019;134(13):1014-1023. doi:10.1182/blood.2019001034